Vertex Pharmaceuticals, Inc.

Timothy J Senter

Jingrong Cao

Jon H Come

Suganthini S Nanthakumar

Leslie A Dakin

Tiansheng Wang

Michael Aaron Brodney

Brian Ledford

Warren A Dorsch

Elaine B Krueger

Anne Fortier

Olivier Nicolas

Camil Sayegh

Francois Maltais

John E Cochran

Claudio F Sturino

Ales Medek

Yi Shi

Peter Jamison Rose

Haoxuan Wang

Kevin Gagnon

Muna Shrestha

Brad D Maxwell

Janek Szychowski

Steven David Stone

Lee Fader

Jessica Howard Olsen

Akira Joseph Shimizu

Francois Denis

Martine Hamel

Kan-Nian Hu

Faith Witkos

Elena Dolgikh

Samantha Angle

Jun Myun Ahn

Hardwin O'Dowd

Stephane Dorich

Stephanie Dorich

Hardwin O′dowd

The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).

Inhibitors of APOL1 and methods of using same

The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

The disclosure provides at least one entity chosen from compounds of Formula (I)

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD). 

Growing community of inventors

Arlington, MA, United States of America

Timothy J Senter